Investigating how TLR4 signaling affects smooth muscle cell changes in atherosclerosis
Role of the TLR4 signaling in smooth muscle cell phenotypic transition
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10886695
This study is looking at how certain signals in the body affect the behavior of smooth muscle cells during atherosclerosis, which can lead to heart disease, and it's specifically checking how a factor called OCT4 influences these changes in specially modified mice.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10886695 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of TLR4 signaling in the changes that smooth muscle cells undergo during the development of atherosclerosis, a condition that can lead to heart disease. The researchers are exploring the molecular mechanisms that drive these changes, particularly how the factor OCT4 influences smooth muscle cell behavior. By studying genetically modified mice, they aim to uncover how these cells transition and what triggers their protective or harmful responses in the context of arterial plaque formation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for atherosclerosis or those with existing cardiovascular conditions.
Not a fit: Patients who do not have cardiovascular risk factors or existing atherosclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating atherosclerosis and related cardiovascular diseases.
How similar studies have performed: Other research has shown promising results in understanding the role of cellular signaling in atherosclerosis, suggesting that this approach could yield valuable insights.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEREPANOVA, OLGA — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: CHEREPANOVA, OLGA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.